Breaking News, Collaborations & Alliances

ABL Inks Vaccine and Biologics Mfg. Pact with NCI

CDMO to provide cGMP manufacturing services in support of the PREVENT Cancer Preclinical Program

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Advanced BioScience Laboratories (ABL), a global contract development and manufacturing organization (CDMO) for biotherapeutics and vaccines, was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under its PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (Solicitation Number: N01CN87006-18). The 4-year multiple-award contract ha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters